The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trail

被引:17
|
作者
Kasting, Monica L. [1 ]
Head, Katharine J. [2 ]
Cox, Dena [3 ]
Cox, Anthony D. [3 ]
Zimet, Gregory D. [4 ]
机构
[1] Purdue Univ, Dept Hlth & Kinesiol, 800 W Stadium Ave, W Lafayette, IN 47907 USA
[2] Indiana Univ Purdue Univ, Dept Commun Studies, 425 Univ Blvd, Indianapolis, IN 46202 USA
[3] Indiana Univ, Kelley Sch Business, 801 W Michigan St, Indianapolis, IN 46202 USA
[4] Indiana Univ, Sch Med, Dept Pediat, 410 W 10th St, Indianapolis, IN 46202 USA
关键词
Prospect theory; Hepatitis B virus; Hepatitis B vaccines; Vaccination; Vaccine uptake; Health communication; Patient acceptance of healthcare; Randomized controlled trial; Health promotion; Framing; HUMAN-PAPILLOMAVIRUS VACCINATION; LOSS-FRAMED MESSAGES; PERCEIVED RISK INFLUENCE; UNITED-STATES; RELATIVE PERSUASIVENESS; ADVISORY-COMMITTEE; HPV VACCINATION; PROSPECT-THEORY; COMMUNICATION; IMMUNIZATION;
D O I
10.1016/j.ypmed.2019.105798
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Many adults in the U.S. do not receive recommended vaccines, and the research literature remains inconclusive on the best communication strategies for increasing this behavior. This study examined the association of message framing (gained-framed vs. loss-framed vs. control), and healthcare provider (HCP) recommendation (offered vs. recommended) on uptake of adult hepatitis B virus (HBV) vaccination in a high risk population using a 3 x 2 block design randomized controlled trial. Fear of shots, fear of vaccines, and perceived message framing were examined in secondary analyses. Of the 1747 participants, 47.7% (n = 833) received 0 doses of HBV vaccine, 27.8% (n = 485) received 1 dose, 10.4% received 2 doses, and 14.1% received all 3 recommended doses. There was not a significant interaction between message framing and HCP recommendation (p = .59). Mean number of doses received by the gain-framed group (m = 0.96) was not significantly different from the loss-framed group (m = 0.97, RR = 0.99, 95% CI = 0.88-1.12). However, those receiving any framing message received significantly more doses (m = 0.96) than those in the control condition (m = 0.81, RR = 1.17, 95%CI = 1.06-1.31). Participants who received a HCP recommendation received significantly more vaccine doses (m = 0.95) than those in the vaccine-offered condition (mean = 0.82, RR = 1.16, 95%CI = 1.05-1.28). These results suggest there is no difference in vaccine uptake between gain-frame and loss-frame messages, but both are better than a control message. These results also support advising HCP to provide a strong recommendation for vaccinations beyond merely offering it to patients. This study has implications for vaccine uptake beyond HBV, and can inform future research on effective vaccine communication research.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Understanding hepatitis B vaccination willingness in the adult population in Indonesia: a survey among outpatient and healthcare workers in community health centers
    Machmud, Putri Bungsu
    Mikolajczyk, Rafael
    Gottschick, Cornelia
    [J]. JOURNAL OF PUBLIC HEALTH-HEIDELBERG, 2023, 31 (12): : 1969 - 1980
  • [22] INTRADERMAL VERSUS INTRAMUSCULAR HEPATITIS B VACCINATION IN HAEMODIALYSIS PATIENTS: A PROSPECTIVE, OPEN LABEL RANDOMIZED CONTROLLED TRIAL IN PATIENTS UNRESPONSIVE TO PRIMARY VACCINATION
    Wiggins, K.
    Van Eps, C.
    Barraclough, K.
    Whitby, M.
    Carpenter, S.
    Johnson, D.
    Johnson, C. H.
    Playford, G.
    [J]. NEPHROLOGY, 2008, 13 : A99 - A100
  • [23] Intradermal Versus Intramuscular Hepatitis B Vaccination in Hemodialysis Patients: A Prospective Open-Label Randomized Controlled Trial in Nonresponders to Primary Vaccination
    Barraclough, Katherine A.
    Wiggins, Kathryn J.
    Hawley, Carmel M.
    van Eps, Carolyn L.
    Mudge, David W.
    Johnson, David W.
    Whitby, Michael
    Carpenter, Sally
    Playford, E. Geoffrey
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (01) : 95 - 103
  • [24] Effects of Prophylactic and Therapeutic Paracetamol Treatment during Vaccination on Hepatitis B Antibody Levels in Adults: Two Open-Label, Randomized Controlled Trials
    Doedee, Anne M. C. M.
    Boland, Greet J.
    Pennings, Jeroen L. A.
    de Klerk, Arja
    Berbers, Guy A. M.
    van der Klis, Fiona R. M.
    de Melker, Hester E.
    van Loveren, Henk
    Janssen, Riny
    [J]. PLOS ONE, 2014, 9 (06):
  • [25] Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study
    Lee, Jeong-Hoon
    Lee, Yun Bin
    Cho, Eun Ju
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E3308 - E3316
  • [26] Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial
    Han, Bingfeng
    Liu, Wu
    Du, Juan
    Liu, Hanyu
    Zhao, Tianshuo
    Yang, Shubo
    Wang, Shuai
    Zhang, Sihui
    Liu, Bei
    Liu, Yaqiong
    Cui, Fuqiang
    [J]. VACCINE, 2021, 39 (25) : 3365 - 3371
  • [27] Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial
    Day, Carolyn A.
    Shanahan, Marian
    Wand, Handan
    Topp, Libby
    Haber, Paul S.
    Rodgers, Craig
    Deacon, Rachel
    Walsh, Nick
    Kaldor, John
    van Beek, Ingrid
    Maher, Lisa
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2016, 74 : 66 - 72
  • [28] Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in HIV/AIDS Patients: A Randomized Controlled Trial
    Sayad, Babak
    Alavian, Seyyed Moayed
    Najafi, Farid
    Soltani, Bita
    Shirvani, Maria
    Janbakhsh, Alireza
    Mansouri, Feyzollah
    Afsharian, Mandana
    Vaziri, Siavash
    Alikhani, Arash
    Bashiri, Homayoon
    [J]. HEPATITIS MONTHLY, 2012, 12 (09)
  • [29] The effects of α-galactosylceramide on chronic hepatitis B infection in a randomized placebo controlled phase I/II trial
    ter Borg, Martijn J.
    Sprengers, Dave
    Woltman, Andrea M.
    von Blomberg, B. Mary E.
    Van Nieuwkerk, Karin C.
    Tielemans, Wanda C.
    Binda, Rekha
    van der Molen, Renate
    Janssen, Harry L.
    [J]. HEPATOLOGY, 2007, 46 (04) : 685A - 686A
  • [30] RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RECOMBINANT INTERLEUKIN-2 IN CHRONIC UREMIC PATIENTS, NONRESPONDERS TO HEPATITIS-B VACCINATION
    JUNGERS, P
    GEFFRIAUDRICOUARD, C
    DAHMANE, D
    FESSI, H
    JUQUEL, JP
    SIMON, N
    DESCHAMPS, A
    MEYRIER, A
    [J]. KIDNEY INTERNATIONAL, 1995, 47 (05) : 1483 - 1483